No Data
Maxim Group Maintains Medicus Pharma(MDCX.US) With Buy Rating, Maintains Target Price $10
Medicus Pharma Ltd Poised for Growth: Buy Rating Reaffirmed Amid Promising Developments and Upcoming Catalysts
Promising Phase 2 Study and Innovative Approach Boost Confidence in Medicus Pharma Ltd.
Medicus Pharma Expects Interim Data From Phase 2 Skin Cancer Trial by Quarter-end | NASDAQ:MDCX, TSX-V:MDCX
Medicus Pharma Advances Phase 2 BCC Clinical Study With FDA Submission Plans
Express News | Medicus Pharma Ltd. Announce That Its Phase 2 Clinical Study (SKNJCT-003) Which Is Currently Underway In Nine Clinical Sites In United States, Has Now Randomized More Than 50% Of 60 Patients Expected To Be Enrolled In The Study
